BIOMAT Database Logo BIOMAT Database Logo

Compensated low-dose 131I therapy of Graves' disease. 1977

C P Roudebush, and K E Hoye, and L J DeGroot

To minimize the high rate of residual thyrotoxicosis encountered in low-dose 131I therapy of Graves' disease, we have treated 62 patients with a low-dose 131I protocol that includes a compensation for thyroid size. Dose varied between 40 muCi retained/g for glands of normal size to 100 muCi/g for glands of 100 g or greater. Mean dose was 51.9 muCi/g. At 1 year after therapy, 66.1% of subjects were euthyroid, 9.7% hypothyroid, and 24.2% hyperthyroid, a significant improvement (P less than 0.01) over our previous experience using 50 muCi/g independent of gland size. Several factors, other than 131I dose, which might influence the outcome of therapy, were investigated. Initial free thyroxine index observed before therapy was found to have prognostic significance. Hypothyroidism developed only in patients having an initial free thyroxine index of 22.5 or less (about 2.5 times the upper limit of normal in our laboratory).

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C P Roudebush, and K E Hoye, and L J DeGroot
Follow-up of compensated low-dose 131I therapy for Graves' disease.
December 1984, The New England journal of medicine,
C P Roudebush, and K E Hoye, and L J DeGroot
Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
August 1984, The New England journal of medicine,
C P Roudebush, and K E Hoye, and L J DeGroot
Low dose 131I in treatment of Graves' disease.
August 1985, Journal of the Royal Society of Medicine,
C P Roudebush, and K E Hoye, and L J DeGroot
Low-dose 131I in treatment of Graves' disease.
March 1985, Journal of the Royal Society of Medicine,
C P Roudebush, and K E Hoye, and L J DeGroot
[Therapy with 131I to hyperthyroidism Graves disease resolution: dose selection].
October 2007, Arquivos brasileiros de endocrinologia e metabologia,
C P Roudebush, and K E Hoye, and L J DeGroot
Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
May 1988, Clinical endocrinology,
C P Roudebush, and K E Hoye, and L J DeGroot
Low-dose 131I fails to hold euthyroidism in Graves' cases.
October 1983, Hospital practice (Office ed.),
C P Roudebush, and K E Hoye, and L J DeGroot
Graves' disease after 131I therapy for toxic nodule.
January 2001, Thyroid : official journal of the American Thyroid Association,
C P Roudebush, and K E Hoye, and L J DeGroot
Graves' ophthalmopathy and 131I therapy.
December 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
C P Roudebush, and K E Hoye, and L J DeGroot
[Thyroid nodule after radioiodine (131I) therapy for Graves' disease].
March 1984, Kaku igaku. The Japanese journal of nuclear medicine,
Copied contents to your clipboard!